27 citations
,
July 2009 in “Experimental and Clinical Endocrinology & Diabetes” This study found that finasteride significantly improved hirsutism scores in women over 12 months and was well-tolerated with no serious side effects.
42 citations
,
October 2004 in “Experimental and Clinical Endocrinology & Diabetes” In this study, PCOS was the most common cause of hirsutism among Turkish women, but about 17% had idiopathic hyperandrogenemia with no clear cause identified.
47 citations
,
March 2004 in “European journal of endocrinology” This study found that the combination of spironolactone and finasteride significantly improved hirsutism scores more than spironolactone alone in women, with similar side-effect profiles between treatments.
12 citations
,
January 2004 in “Reproductive biomedicine online” This review discusses the main features of anti-androgen drugs, combined treatments, and insulin sensitizers in managing hirsutism and reports no new research findings.
195 citations
,
May 2003 in “Obstetrics and gynecology (New York. 1953. Online)/Obstetrics and gynecology” This review discusses the diagnosis and treatment of hirsutism, emphasizing that a systematic evaluation can determine its cause, while combination therapy effectively manages the condition for most patients.
56 citations
,
April 2003 in “Fertility and Sterility” This study found that while cyproterone acetate, finasteride, and spironolactone had similar short-term effects in treating idiopathic hirsutism, spironolactone provided more lasting benefits one year after treatment.
164 citations
,
January 2003 in “Drugs” 
18 citations
,
January 2003 in “Gynecological Endocrinology” In this study, low-dose finasteride (2.5 mg/day) significantly reduced hirsutism scores in women over 12 months without significant hormonal changes or serious side effects.
51 citations
,
October 2002 in “European journal of endocrinology” This study found that both high-dose and low-dose finasteride significantly reduced hirsutism scores in women after 12 months, with the lower dose being safe and cost-effective.
63 citations
,
March 2001 in “Fertility and Sterility” This study found that Diane 35 combined with finasteride led to a greater reduction in hirsutism scores over 12 months compared to Diane 35 alone.
22 citations
,
March 2000 in “Clinical endocrinology” This study found that while ethinyl oestradiol and cyproterone acetate effectively treated hirsutism in 90% of patients, 80% experienced relapse within six months after stopping treatment, suggesting long-term use is necessary.
46 citations
,
January 2000 in “The Journal of Clinical Endocrinology and Metabolism” 
216 citations
,
November 1999 in “Fertility and Sterility” This study found that a basal 17-hydroxyprogesterone level is effective for screening nonclassic adrenal hyperplasia in women, with a 4 ng/mL cutoff providing high specificity and positive predictive value.
75 citations
,
October 1999 in “European journal of endocrinology” This study found that both finasteride and flutamide effectively reduce hirsutism in women with polycystic ovary syndrome or idiopathic hirsutism, but flutamide was more effective.
23 citations
,
April 1999 in “The Journal of Clinical Endocrinology and Metabolism” This study found that flutamide, finasteride, ketoconazole, and EE-CPA all significantly reduced hirsutism scores, hair diameter, and hair growth rate in women with hirsutism over 12 months.
75 citations
,
March 1999 in “Fertility and sterility” This study concluded that finasteride, cyproterone acetate, and flutamide were similarly effective at reducing hirsutism in women, though they acted through different mechanisms.
76 citations
,
December 1997 in “Fertility and Sterility” This study found that spironolactone was significantly more effective than finasteride in reducing hirsutism scores over 9 months, despite more side effects occurring in the spironolactone group.
30 citations
,
April 1997 in “European journal of endocrinology” The document concludes that managing hirsutism involves identifying the cause, using a scoring system for severity, combining cosmetic and medical treatments, encouraging weight loss, and providing psychological support, while noting the need for more research on drug treatments.
61 citations
,
September 1994 in “The Journal of Clinical Endocrinology and Metabolism” 94 citations
,
July 1991 in “Clinical endocrinology” In this study, cyproterone acetate at 2 mg daily was found to be as effective as higher doses in reducing hair growth for hirsute women over 12 months.
43 citations
,
May 1986 in “Clinics in Endocrinology and Metabolism” This review examines androgen status in male and female obesity and its influence on the metabolic syndrome, but reports no new clinical results.
